Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Delcath Systems Inc

DCTH

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Last trade $19.60
Day change -$0.27 (-1.36%)
Day range $19.38 – $20.07
Volume 253,037
Market cap $691M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$691.24M
Price / earnings
103.88×
Price / book
5.18×
Price / sales
6.29×
EV / sales
5.78×
EV / EBITDA
103.57×

Profitability

Earnings per share
$0.19
Return on assets
4.46%
Return on equity
4.98%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
10.87×
Quick ratio
10.06×
Cash ratio
4.26×

Cash flow

Price / cash flow
30.06×
Price / free cash flow
34.37×
Free cash flow
$20.11M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for DCTH, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$35.1M$29.13M$24.99M$20.73M$20.56M$24.16M$19.78M$15.1M
Cost of revenue$3.92M$2.99M$3.74M$3.01M$2.62M$3.32M$2.85M$2.13M
Gross profit$31.18M$26.15M$21.26M$17.72M$17.94M$20.84M$16.94M$12.97M
Selling, general and administrative$13.06M$13.37M$13.07M$10.53M$10.34M$11.37M$11.29M$7.02M
Research and development$11.01M$10.38M$9.82M$9.37M$7.99M$6.88M$5.01M$2.91M
Total operating expenses$24.07M$23.75M$22.9M$19.9M$18.33M$18.25M$16.3M$9.94M
Operating income$7.12M$2.4M-$1.64M-$2.18M-$388K$2.59M$642K$3.04M
Interest expense$0$781K$787K$0$0$649K$618K$0
Income before taxes$7.97M$3.16M-$908K-$1.33M$375K$3.21M$1.26M-$3.4M
Income taxes$1.02M$491K$162K$562K-$455K$508K$195K$0
Net income$6.95M$2.67M-$1.07M-$1.9M$830K$2.7M$1.07M-$3.4M
Net income attributable to common shareholders$6.95M$2.67M-$1.07M-$1.9M$830K$2.7M$1.07M-$3.4M
EBITDA$7.27M$2.51M-$1.54M-$2.1M-$324K$2.64M$685K$3.08M
Basic earnings per share$0.19$0.07-$0.03-$0.05$0.02$0.08$0.03-$0.11
Diluted earnings per share$0.17$0.07-$0.03-$0.05$0.02$0.07$0.03-$0.12

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable

Delcath Systems (DCTH) has gained 27.6% over 12 weeks and 44.4% over the past four weeks, trading at 92.2% of its 52-week high. The stock carries a Zacks Rank #1 (Strong Buy) rating with an Average Broker Recommendation of #1, indicating strong fundamental strength and potential for continued upward momentum.

Zacks Investment Research

Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy?

Delcath Systems (DCTH) has been identified as a strong momentum stock with a Zacks Rank #1 (Strong Buy) rating and Momentum Style Score of A. The stock has shown impressive performance with a 47.89% monthly gain and 153.43% yearly gain, significantly outperforming the S&P 500. Recent earnings estimate revisions have moved upward, with consensus estimates improving from -$0.17 to $0.13 in the past 60 days.

Zacks Investment Research

Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 27.7%: Read This Before Placing a Bet

Delcath Systems (DCTH) has a mean analyst price target of $27.8, suggesting 27.7% upside potential from its current $21.77 price. The stock has gained 47.9% over the past four weeks. Analysts have revised earnings estimates higher, and DCTH holds a Zacks Rank #1 (Strong Buy) rating. However, the article cautions that price targets can be misleading and should not be the sole basis for investment decisions.

Zacks Investment Research

Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?

CryoPort, Inc. (CYRX) has returned 81.3% year-to-date, significantly outperforming the Medical sector's 1.6% average return. The company holds a Zacks Rank #2 (Buy) with improving earnings outlook. Delcath Systems, Inc. (DCTH) has also outperformed with a 58.1% year-to-date return and a Zacks Rank #1 (Strong Buy), supported by an 80.7% increase in consensus EPS estimates over three months.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Dec 24, 20191-for-700reverse split
May 2, 20181-for-500reverse split
Nov 6, 20171-for-350reverse split
Jul 21, 20161-for-16reverse split
Apr 9, 20141-for-16reverse split